Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?
Ann Rheum Dis
.
2019 Apr;78(4):e28.
doi: 10.1136/annrheumdis-2018-213340.
Epub 2018 Apr 13.
Authors
Benjamin A Fisher
1
2
3
,
Paul Emery
4
5
,
Costantino Pitzalis
6
,
Michele Bombardieri
6
,
Simon J Bowman
1
2
3
Affiliations
1
National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.
2
Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
3
Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
4
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, London, UK.
5
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
6
William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, UK.
PMID:
29653928
DOI:
10.1136/annrheumdis-2018-213340
No abstract available
Keywords:
sjøgren’s syndrome; treatment; ultrasonography.
Publication types
Letter
Comment
MeSH terms
Double-Blind Method
Humans
Rituximab
Salivary Glands
Sjogren's Syndrome*
Ultrasonography
Substances
Rituximab
Grants and funding
MR/N003063/1/MRC_/Medical Research Council/United Kingdom